Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD
Novel subcutaneous delivery may offer a more patient-friendly alternative to intravitreal injections, with the potential to significantly reduce treatment burden
REDWOOD CITY, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics ('Ashvattha'), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced interim results from its ongoing Phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (wet-AMD). The data were presented at the MaculArt Meeting, June 29 – July 1, 2025 in Paris.
MGB represents a potential alternative to current standard of care, which requires patients to receive intravitreal injections every 4 to 12 weeks in a clinical setting. MGB is a first-in-class subcutaneously administered candidate being developed for convenient, at-home monthly treatment of DME and wet AMD, aiming to reduce treatment burden while avoiding systemic side effects.
Unlike current anti-VEGF therapies that require repeated intravitreal injections directly into the eye, subcutaneously (subQ) administered MGB provides a unique mechanism of action of normalizing vascular endothelial growth factor (VEGF) expression in activated macrophages, microglia and retinal pigment epithelial cells in the retina. By reducing VEGF expression, MGB reduces the need for anti-VEGF intravitreal injections improving patient adherence.
Key Phase 2 Interim Results (24-week data):
Data presented in the presentation titled ' Subcutaneous Migaldendranib (MGB) for the Treatment of Neovascular Age-Related Macular Degenerations and Diabetic Macular Edema: Interim Results of Chronic Dosing Phase 2 Study' showed that subQ MGB demonstrated promising safety and tolerability in both DME and wet-AMD patients in the first 24 weeks of treatment. The study used more conservative supplement criteria compared to other recent clinical studies, with rescue anti-VEGF injections given when central subfield thickness increased above baseline, rather than the >75 μm increase from lowest value used in other studies. The interim analysis included 19 subjects who completed 24 weeks (11 wet AMD, 8 DME).
Results:
These interim results support MGB's potential in decreasing the need for supplemental intravitreal injections of anti-VEGF, suggesting a potential new treatment pathway for patients. End of study results will be presented at an upcoming conference.
'These results demonstrate a potential paradigm shift in the treatment of DME and wet-AMD patients,' said Jeff Cleland, PhD, CEO of Ashvattha Therapeutics. 'The interim Phase 2 data support the potential of subcutaneous MGB to offer patients a convenient, once-monthly alternative to frequent eye injections. By targeting inflammation and fluid accumulation in both eyes with a single systemic dose, we may be able to significantly reduce treatment burden and improve quality of life. We look forward to advancing this novel treatment for DME and wet-AMD and to bringing a new treatment forward for patients who need it most.'
These data were also presented at the Clinical Trials at the Summit, June 21, 2025, in Las Vegas.
About Ashvattha Therapeutics
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, oncology, and inflammation. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com
Media
ICR Healthcare
[email protected]
Investor Relations
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075
Yahoo
7 hours ago
- Yahoo
Strongest Appetite Suppressant Over the Counter Now Available in USA - PhenQ Medically Accredited Craving Control Supplement OTC
Clinicians' Choice Appetite Suppressant, PhenQ: Medically Accredited by 800 Professionals and Now Launched in the USA Without Prescription Phenq New York City, NY, June 30, 2025 (GLOBE NEWSWIRE) -- For Americans seeking the most effective, safe, and convenient way to control food cravings and promote weight loss, a breakthrough is here. PhenQ, the strongest appetite suppressant over the counter (OTC), has officially launched in the United States and worldwide—earning the rare and coveted 'clinicians' choice' status after being medically accredited by over 800 medical professionals. For men and women looking to lose weight, manage appetite, and improve overall health without the risks of prescription appetite suppressants or weight loss drugs, PhenQ is the OTC appetite suppressant the world has been waiting for. Product Launch: A New Era for Clinician-Backed OTC Appetite Suppressants PhenQ's arrival marks a turning point in the world of weight loss supplements. For decades, Americans have struggled to find effective appetite suppressant pills that are both safe and available without a prescription. Prescription appetite suppressants and weight loss drugs often require doctor supervision, can lead to high blood pressure, and may not be suitable for those with a higher body mass index or specific health concerns. Now, with PhenQ, users can experience the best appetite suppressant over the counter, with a formula that has been medically accredited, approved, and recommended by over 800 clinicians. This level of medical endorsement is a rarity for OTC appetite suppressants, making PhenQ the clear leader in the category. Main PhenQ Benefits & Features PhenQ delivers a multi-faceted approach to weight loss and appetite control. Here's what makes it the most effective appetite suppressant OTC and a top choice for weight management: 1. Clinically Proven Appetite Suppressant PhenQ's formula contains α-Lacys Reset®, a patented complex that accelerates metabolism and promotes thermogenesis, helping users suppress appetite and burn calories more efficiently. Clinical studies have shown that people using α-Lacys Reset® lost up to 7.24% of body fat, 3.44% of body weight, and gained 3.8% muscle mass, making it a unique weight loss supplement for those looking to lose weight while retaining lean muscle. 2. Reduces Food Cravings Through its blend of chromium picolinate, nopal cactus, and natural caffeine, PhenQ helps reduce cravings for sweets and carbs. This powerful appetite suppressant formula is designed to help users stay on track, avoid emotional eating, and break the cycle of late-night snacking. 3. Promotes Weight Loss and Fat Burning PhenQ combines thermogenic agents like Capsimax powder (a blend of capsicum, piperine, caffeine, and niacin) to ignite fat burning and help users reach their weight loss goals faster. This is not just an appetite suppressant, but a comprehensive weight loss supplement for total body transformation. 4. Enhances Energy and Mood Unlike many diet pills or prescription appetite suppressants that can cause fatigue or mood swings, PhenQ contains caffeine, nopal, and L-carnitine to provide all-day energy and cognitive support. This keeps users motivated, focused, and ready to conquer their health and fitness journey. 5. Supports Normal Appetite and Keto Lifestyles PhenQ is a natural appetite suppressant that fits perfectly into keto or low-carb diets, helping users manage appetite and maintain healthy eating habits for sustainable weight loss. 6. No Prescription Required—100% OTC As one of the strongest OTC appetite suppressants, PhenQ is available for purchase without a prescription. This makes appetite control more accessible than ever for millions of Americans. 7. Vegan & Vegetarian Friendly PhenQ is made from 100% vegan and vegetarian ingredients, ensuring inclusivity for a wide variety of dietary needs. Company Name and Location PhenQ (USA)Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United KingdomDistributed in the USA, Canada, UK, Australia and globally PhenQ Pricing Details PhenQ is competitively priced with attractive savings for multi-bottle purchases and includes a risk-free guarantee: 1 Bottle: $69.99 (Retail $79.99) — 1 Month Supply 2 Bottles + 1 Free: $139.99 (Retail $239.99) — 3 Month Supply (Most Popular) 3 Bottles + 2 Free: $209.99 (Retail $399.99) — 5 Month Supply (Best Value) Free Shipping: On all orders over $79.99 60-Day Money-Back Guarantee: Try it risk-free Order and see current offers at official PhenQ website Launch Date & Availability PhenQ is now available to buy OTC in the United States and ships to over 190 countries. Orders are processed and shipped within 24–48 hours from warehouses in the US, UK, and Germany. PhenQ is also now available for purchase worldwide, providing rapid delivery and discreet packaging. Scientific Data and Studies PhenQ's appetite suppressant formula is backed by clinical research: α-Lacys Reset®: Clinical trials published in peer-reviewed journals demonstrate significant reductions in body weight, body fat, and increased muscle mass compared to placebo. Capsimax Powder: Research in Bioscience Report highlights the ability of capsaicinoids to increase thermogenesis and potentially stop the formation of new fat cells. Chromium Picolinate: An eight-week Cornell University study showed chromium supplementation helps reduce carb cravings and supports healthy blood sugar levels. Caffeine: Multiple studies confirm caffeine's ability to suppress appetite, increase alertness, and boost metabolic rate. Nopal Cactus: Rich in fiber and amino acids, nopal helps manage appetite, increase satiety, and reduce fluid retention. References: Whiting S, Derbyshire E, Tiwari BK. (2012) Appetite Control. Zemel MB, Thompson W, Milstead A, et al. (2004) Obesity Research. Docherty JP, Sack DA, et al. (2005) Journal of Psychiatry Practice. Health & Safety Benefits PhenQ is designed as a safe, effective alternative to prescription appetite suppressants and weight loss drugs: All-Natural Appetite Suppressant: PhenQ includes only natural, high-grade ingredients with a strong safety record. No Major Side Effects: No prescription required, and hundreds of thousands of users have reported no significant adverse effects. Suitable for Long-Term Use: Can be used as long as needed for weight management, unlike some weight loss drugs that are only approved for short-term use. No Habit-Forming Ingredients: Unlike some prescription appetite suppressants, PhenQ is non-addictive and safe for ongoing use. Made in FDA & GMP Approved Facilities: All manufacturing is done under strict quality controls in the US and UK. Scientific Innovation of OTC Weight Loss Supplements What makes PhenQ a leader among OTC appetite suppressants and diet pills? Multi-Action Formula: Combines the strongest ingredients for appetite control, fat burning, energy, and mood—unlike most other weight loss supplements that target a single aspect. α-Lacys Reset®: A unique, trademarked, and scientifically validated ingredient at the heart of PhenQ's effectiveness. Synergy of Ingredients: Each component supports the others for a holistic approach to appetite suppression and weight management. Transparency: Full ingredient disclosure and clinical research citations—no hidden blends or proprietary secrets. OTC Diet Pills Market Disruption PhenQ is fundamentally disrupting the appetite suppressant and weight loss supplement industry: Medically Studied by 800 Professionals: PhenQ's 'clinicians' choice' status is nearly impossible to attain and sets a new bar for OTC appetite suppressant pills. Outperforms Prescription Appetite Suppressants: Without the need for a prescription or risk of high blood pressure and other side effects, PhenQ is safer and more accessible. Superior to Traditional Diet Pills: PhenQ's multi-pronged formula makes it more effective than many single-purpose appetite suppressant pills or dietary supplements. No Prescription, No Hassle: PhenQ brings prescription-level results to the OTC market—no waiting rooms, no doctor's approval necessary. Consumer Benefits Users of PhenQ enjoy a wide range of benefits—making it the strongest and most trusted OTC appetite suppressant available: Strongest Appetite Suppressant OTC: Clinically proven to suppress appetite, crush cravings, and help users lose weight effectively. Promotes Weight Loss: Helps reduce calorie intake, supports fat burning, and assists in lowering body weight and body mass index. Appetite Control and Satiety: Natural ingredients help users feel full, satisfied, and in control of their eating habits. Counter Appetite and Emotional Eating: Reduces stress-related snacking and helps break the cycle of emotional eating. Supports Healthy Weight Management: Sustained use assists in long-term maintenance of healthy weight, reducing the risk of regaining lost pounds. Safe for Most Adults: No major side effects, no habit-forming components, and suitable for both men and women. Fits Modern Lifestyles: Only two pills per day, no drastic diet changes required, and works with keto and other popular diets. Money-Back Guarantee: If you're not satisfied, get a full refund within 60 days—no questions asked. Quote from PhenQ Spokesperson 'PhenQ is the result of years of scientific research and clinical study. To be named a clinicians' choice by over 800 medical professionals is an extraordinary honor—and a testament to our commitment to safety, effectiveness, and transparency. As the strongest OTC appetite suppressant available today, PhenQ is helping people in the USA and around the world take control of their appetite, lose weight safely, and achieve lasting health.'— Kay Norris, Product Innovation, PhenQ Distribution Channels Direct-to-Consumer: Only available from the official site to guarantee authenticity and best pricing. Worldwide Shipping: To over 190 countries, with free shipping on orders over $79.99. Discreet Packaging: All orders shipped in plain packaging for your privacy. Website URL & Contact Person Details Website: Email: support@ Phone: +1 (646) 513 2632 For media inquiries:Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ Safety Certifications & Testing FDA & GMP Approved Facilities: Manufactured to the highest US and UK standards. Third-Party Lab Testing: For purity, potency, and safety. Full Ingredient Transparency: No hidden blends or undisclosed substances. Vegan & Vegetarian Safe: 100% plant-based ingredients. Product Usage & Dosage Recommended Use: Take one PhenQ pill with breakfast and one with lunch. Do Not Exceed Recommended Dose: Due to natural caffeine content, avoid taking after 3pm. Long-Term Use: Safe for ongoing appetite control and weight management. Appetite Suppressants in the Modern Age: How PhenQ Changes the Game Appetite suppressants work by helping users feel full, reduce food cravings, and lower overall calorie intake. However, most prescription appetite suppressants and weight loss drugs come with potential side effects, high blood pressure risks, and often require strict medical supervision. OTC appetite suppressants like PhenQ are changing this landscape by providing a safe, effective, and accessible solution for Americans struggling with weight management. PhenQ's unique composition of scientifically proven ingredients sets it apart from alli weight loss pill and other common dietary supplements. It is not just a diet pill; it is a comprehensive, medically endorsed appetite suppressant designed to suppress cravings, promote weight loss, and support lasting health. Conclusion: The Future of Appetite Control Is Here PhenQ is the strongest appetite suppressant over the counter now available in the USA and worldwide—backed by 800 medical professionals and trusted by nearly 200,000 satisfied customers. With its powerful, natural appetite suppressant formula, robust clinical validation, and unmatched safety profile, PhenQ is setting a new standard for OTC appetite suppressants and weight management. About PhenQ (USA) / Wolfson BrandsPhenQ is produced by Wolfson Brands, a global leader in health innovation. With a focus on science, safety, and customer success, PhenQ continues to redefine what's possible in appetite suppressant pills and weight loss supplements. Media Contact:Kay Norris, Head of Product InnovationWolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a physician before Phenq CONTACT: For media inquiries: Website: Email: support@ Phone: +1 (646) 513 2632 Wolfson Brands (UK) Limited 12 Payne Street, Glasgow, G4 0LF, United Kingdom support@ in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Strongest Appetite Suppressant Over the Counter Now Available in USA - PhenQ Medically Accredited Craving Control Supplement OTC
Clinicians' Choice Appetite Suppressant, PhenQ: Medically Accredited by 800 Professionals and Now Launched in the USA Without Prescription Phenq New York City, NY, June 30, 2025 (GLOBE NEWSWIRE) -- For Americans seeking the most effective, safe, and convenient way to control food cravings and promote weight loss, a breakthrough is here. PhenQ, the strongest appetite suppressant over the counter (OTC), has officially launched in the United States and worldwide—earning the rare and coveted 'clinicians' choice' status after being medically accredited by over 800 medical professionals. For men and women looking to lose weight, manage appetite, and improve overall health without the risks of prescription appetite suppressants or weight loss drugs, PhenQ is the OTC appetite suppressant the world has been waiting for. Product Launch: A New Era for Clinician-Backed OTC Appetite Suppressants PhenQ's arrival marks a turning point in the world of weight loss supplements. For decades, Americans have struggled to find effective appetite suppressant pills that are both safe and available without a prescription. Prescription appetite suppressants and weight loss drugs often require doctor supervision, can lead to high blood pressure, and may not be suitable for those with a higher body mass index or specific health concerns. Now, with PhenQ, users can experience the best appetite suppressant over the counter, with a formula that has been medically accredited, approved, and recommended by over 800 clinicians. This level of medical endorsement is a rarity for OTC appetite suppressants, making PhenQ the clear leader in the category. Main PhenQ Benefits & Features PhenQ delivers a multi-faceted approach to weight loss and appetite control. Here's what makes it the most effective appetite suppressant OTC and a top choice for weight management: 1. Clinically Proven Appetite Suppressant PhenQ's formula contains α-Lacys Reset®, a patented complex that accelerates metabolism and promotes thermogenesis, helping users suppress appetite and burn calories more efficiently. Clinical studies have shown that people using α-Lacys Reset® lost up to 7.24% of body fat, 3.44% of body weight, and gained 3.8% muscle mass, making it a unique weight loss supplement for those looking to lose weight while retaining lean muscle. 2. Reduces Food Cravings Through its blend of chromium picolinate, nopal cactus, and natural caffeine, PhenQ helps reduce cravings for sweets and carbs. This powerful appetite suppressant formula is designed to help users stay on track, avoid emotional eating, and break the cycle of late-night snacking. 3. Promotes Weight Loss and Fat Burning PhenQ combines thermogenic agents like Capsimax powder (a blend of capsicum, piperine, caffeine, and niacin) to ignite fat burning and help users reach their weight loss goals faster. This is not just an appetite suppressant, but a comprehensive weight loss supplement for total body transformation. 4. Enhances Energy and Mood Unlike many diet pills or prescription appetite suppressants that can cause fatigue or mood swings, PhenQ contains caffeine, nopal, and L-carnitine to provide all-day energy and cognitive support. This keeps users motivated, focused, and ready to conquer their health and fitness journey. 5. Supports Normal Appetite and Keto Lifestyles PhenQ is a natural appetite suppressant that fits perfectly into keto or low-carb diets, helping users manage appetite and maintain healthy eating habits for sustainable weight loss. 6. No Prescription Required—100% OTC As one of the strongest OTC appetite suppressants, PhenQ is available for purchase without a prescription. This makes appetite control more accessible than ever for millions of Americans. 7. Vegan & Vegetarian Friendly PhenQ is made from 100% vegan and vegetarian ingredients, ensuring inclusivity for a wide variety of dietary needs. Company Name and Location PhenQ (USA)Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United KingdomDistributed in the USA, Canada, UK, Australia and globally PhenQ Pricing Details PhenQ is competitively priced with attractive savings for multi-bottle purchases and includes a risk-free guarantee: 1 Bottle: $69.99 (Retail $79.99) — 1 Month Supply 2 Bottles + 1 Free: $139.99 (Retail $239.99) — 3 Month Supply (Most Popular) 3 Bottles + 2 Free: $209.99 (Retail $399.99) — 5 Month Supply (Best Value) Free Shipping: On all orders over $79.99 60-Day Money-Back Guarantee: Try it risk-free Order and see current offers at official PhenQ website Launch Date & Availability PhenQ is now available to buy OTC in the United States and ships to over 190 countries. Orders are processed and shipped within 24–48 hours from warehouses in the US, UK, and Germany. PhenQ is also now available for purchase worldwide, providing rapid delivery and discreet packaging. Scientific Data and Studies PhenQ's appetite suppressant formula is backed by clinical research: α-Lacys Reset®: Clinical trials published in peer-reviewed journals demonstrate significant reductions in body weight, body fat, and increased muscle mass compared to placebo. Capsimax Powder: Research in Bioscience Report highlights the ability of capsaicinoids to increase thermogenesis and potentially stop the formation of new fat cells. Chromium Picolinate: An eight-week Cornell University study showed chromium supplementation helps reduce carb cravings and supports healthy blood sugar levels. Caffeine: Multiple studies confirm caffeine's ability to suppress appetite, increase alertness, and boost metabolic rate. Nopal Cactus: Rich in fiber and amino acids, nopal helps manage appetite, increase satiety, and reduce fluid retention. References: Whiting S, Derbyshire E, Tiwari BK. (2012) Appetite Control. Zemel MB, Thompson W, Milstead A, et al. (2004) Obesity Research. Docherty JP, Sack DA, et al. (2005) Journal of Psychiatry Practice. Health & Safety Benefits PhenQ is designed as a safe, effective alternative to prescription appetite suppressants and weight loss drugs: All-Natural Appetite Suppressant: PhenQ includes only natural, high-grade ingredients with a strong safety record. No Major Side Effects: No prescription required, and hundreds of thousands of users have reported no significant adverse effects. Suitable for Long-Term Use: Can be used as long as needed for weight management, unlike some weight loss drugs that are only approved for short-term use. No Habit-Forming Ingredients: Unlike some prescription appetite suppressants, PhenQ is non-addictive and safe for ongoing use. Made in FDA & GMP Approved Facilities: All manufacturing is done under strict quality controls in the US and UK. Scientific Innovation of OTC Weight Loss Supplements What makes PhenQ a leader among OTC appetite suppressants and diet pills? Multi-Action Formula: Combines the strongest ingredients for appetite control, fat burning, energy, and mood—unlike most other weight loss supplements that target a single aspect. α-Lacys Reset®: A unique, trademarked, and scientifically validated ingredient at the heart of PhenQ's effectiveness. Synergy of Ingredients: Each component supports the others for a holistic approach to appetite suppression and weight management. Transparency: Full ingredient disclosure and clinical research citations—no hidden blends or proprietary secrets. OTC Diet Pills Market Disruption PhenQ is fundamentally disrupting the appetite suppressant and weight loss supplement industry: Medically Studied by 800 Professionals: PhenQ's 'clinicians' choice' status is nearly impossible to attain and sets a new bar for OTC appetite suppressant pills. Outperforms Prescription Appetite Suppressants: Without the need for a prescription or risk of high blood pressure and other side effects, PhenQ is safer and more accessible. Superior to Traditional Diet Pills: PhenQ's multi-pronged formula makes it more effective than many single-purpose appetite suppressant pills or dietary supplements. No Prescription, No Hassle: PhenQ brings prescription-level results to the OTC market—no waiting rooms, no doctor's approval necessary. Consumer Benefits Users of PhenQ enjoy a wide range of benefits—making it the strongest and most trusted OTC appetite suppressant available: Strongest Appetite Suppressant OTC: Clinically proven to suppress appetite, crush cravings, and help users lose weight effectively. Promotes Weight Loss: Helps reduce calorie intake, supports fat burning, and assists in lowering body weight and body mass index. Appetite Control and Satiety: Natural ingredients help users feel full, satisfied, and in control of their eating habits. Counter Appetite and Emotional Eating: Reduces stress-related snacking and helps break the cycle of emotional eating. Supports Healthy Weight Management: Sustained use assists in long-term maintenance of healthy weight, reducing the risk of regaining lost pounds. Safe for Most Adults: No major side effects, no habit-forming components, and suitable for both men and women. Fits Modern Lifestyles: Only two pills per day, no drastic diet changes required, and works with keto and other popular diets. Money-Back Guarantee: If you're not satisfied, get a full refund within 60 days—no questions asked. Quote from PhenQ Spokesperson 'PhenQ is the result of years of scientific research and clinical study. To be named a clinicians' choice by over 800 medical professionals is an extraordinary honor—and a testament to our commitment to safety, effectiveness, and transparency. As the strongest OTC appetite suppressant available today, PhenQ is helping people in the USA and around the world take control of their appetite, lose weight safely, and achieve lasting health.'— Kay Norris, Product Innovation, PhenQ Distribution Channels Direct-to-Consumer: Only available from the official site to guarantee authenticity and best pricing. Worldwide Shipping: To over 190 countries, with free shipping on orders over $79.99. Discreet Packaging: All orders shipped in plain packaging for your privacy. Website URL & Contact Person Details Website: Email: support@ Phone: +1 (646) 513 2632 For media inquiries:Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ Safety Certifications & Testing FDA & GMP Approved Facilities: Manufactured to the highest US and UK standards. Third-Party Lab Testing: For purity, potency, and safety. Full Ingredient Transparency: No hidden blends or undisclosed substances. Vegan & Vegetarian Safe: 100% plant-based ingredients. Product Usage & Dosage Recommended Use: Take one PhenQ pill with breakfast and one with lunch. Do Not Exceed Recommended Dose: Due to natural caffeine content, avoid taking after 3pm. Long-Term Use: Safe for ongoing appetite control and weight management. Appetite Suppressants in the Modern Age: How PhenQ Changes the Game Appetite suppressants work by helping users feel full, reduce food cravings, and lower overall calorie intake. However, most prescription appetite suppressants and weight loss drugs come with potential side effects, high blood pressure risks, and often require strict medical supervision. OTC appetite suppressants like PhenQ are changing this landscape by providing a safe, effective, and accessible solution for Americans struggling with weight management. PhenQ's unique composition of scientifically proven ingredients sets it apart from alli weight loss pill and other common dietary supplements. It is not just a diet pill; it is a comprehensive, medically endorsed appetite suppressant designed to suppress cravings, promote weight loss, and support lasting health. Conclusion: The Future of Appetite Control Is Here PhenQ is the strongest appetite suppressant over the counter now available in the USA and worldwide—backed by 800 medical professionals and trusted by nearly 200,000 satisfied customers. With its powerful, natural appetite suppressant formula, robust clinical validation, and unmatched safety profile, PhenQ is setting a new standard for OTC appetite suppressants and weight management. About PhenQ (USA) / Wolfson BrandsPhenQ is produced by Wolfson Brands, a global leader in health innovation. With a focus on science, safety, and customer success, PhenQ continues to redefine what's possible in appetite suppressant pills and weight loss supplements. Media Contact:Kay Norris, Head of Product InnovationWolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a physician before Phenq CONTACT: For media inquiries: Website: Email: support@ Phone: +1 (646) 513 2632 Wolfson Brands (UK) Limited 12 Payne Street, Glasgow, G4 0LF, United Kingdom support@ in to access your portfolio
